Or­biMed, J&J back $24M A round for mi­cro­bio­me start­up; Sang­amo, Pfiz­er win FDA fast track

→ A new mi­cro­bio­me start­up, Is­rael’s Bio­mX, has raised $24 mil­lion in a Se­ries A — Or­biMed, John­son & John­son In­no­va­tion and Take­da Ven­tures were …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA